SG11201900815UA - Expression of pten-long with ocolytic viruses - Google Patents

Expression of pten-long with ocolytic viruses

Info

Publication number
SG11201900815UA
SG11201900815UA SG11201900815UA SG11201900815UA SG11201900815UA SG 11201900815U A SG11201900815U A SG 11201900815UA SG 11201900815U A SG11201900815U A SG 11201900815UA SG 11201900815U A SG11201900815U A SG 11201900815UA SG 11201900815U A SG11201900815U A SG 11201900815UA
Authority
SG
Singapore
Prior art keywords
international
pct
pten
rule
long
Prior art date
Application number
SG11201900815UA
Inventor
Balveen Kaur
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of SG11201900815UA publication Critical patent/SG11201900815UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

100 80 FIG. 5A 40 60 Days p=0.0437 100 50 as a) n= Med. surv. 12 30.5- , — saline control 9 72 HSVQ=1e5/ms Und RAPTOR=1e5/ms (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIPO I PCT onion °nolo ommill oil HE turnoff oimIE (10) International Publication Number WO 2018/023114 Al (51) International Patent Classification: A61K 35/76 (2015.01) A61K 39/21 (2006.01) A61K 35/761 (2015.01) A61K 48/00 (2006.01) A61K 35/763 (2015.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/044683 (22) International Filing Date: 31 July 2017 (31.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/368,822 29 July 2016 (29.07.2016) US 62/479,671 31 March 2017 (31.03.2017) US (71) Applicant: OHIO STATE INNOVATION FOUN- DATION [US/US]; 1524 North High Street, Columbus, Ohio 43201 (US). (72) Inventor: KAUR, Balveen; 6431 Fannin St MSE.R164, Houston, Texas 77030 (US). (74) Agent: LANIER, J. Gibson et al.; Meunier Carlin & Curf- man LLC, 999 Peachtree St. NE, Suite 1300, Atlanta, Geor- gia 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: EXPRESSION OF PTEN-LONG WITH OCOLYTIC VIRUSES FVB/N - DB7dsRed breast cancer 1-1 O e ft s (57) : Disclosed are novel modified viruses comprising recombinant PTEN-Long and methods of using the same for treating cancer.
SG11201900815UA 2016-07-29 2017-07-31 Expression of pten-long with ocolytic viruses SG11201900815UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662368822P 2016-07-29 2016-07-29
US201762479671P 2017-03-31 2017-03-31
PCT/US2017/044683 WO2018023114A1 (en) 2016-07-29 2017-07-31 Expression of pten-long with ocolytic viruses

Publications (1)

Publication Number Publication Date
SG11201900815UA true SG11201900815UA (en) 2019-02-27

Family

ID=61016870

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900815UA SG11201900815UA (en) 2016-07-29 2017-07-31 Expression of pten-long with ocolytic viruses

Country Status (10)

Country Link
US (2) US20200085890A1 (en)
EP (1) EP3490574B1 (en)
JP (2) JP2019523008A (en)
KR (1) KR20190035782A (en)
CN (1) CN110087662A (en)
AU (1) AU2017301901A1 (en)
BR (1) BR112019001737A2 (en)
CA (1) CA3032412A1 (en)
SG (1) SG11201900815UA (en)
WO (1) WO2018023114A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
JP2020513248A (en) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． Affinity cell extraction by sound
BR112020009889A2 (en) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acoustic transducer driver and controller
CN108484780A (en) * 2018-04-16 2018-09-04 河南大学 A kind of fusion protein PTEN-L-p53 and its application
WO2020208609A1 (en) 2019-04-12 2020-10-15 Therapten Biosciences Inc. Compositions and methods to manufacture phosphatase and tensin homolog (pten) fusions
WO2021024207A1 (en) * 2019-08-05 2021-02-11 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
CN111763260B (en) * 2020-06-11 2022-03-29 四川大学华西医院 PTEN-Long polyclonal antibody, preparation method and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (en) 1968-10-17 1970-08-24
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
US20080292592A1 (en) * 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
CN101180397A (en) * 2005-03-09 2008-05-14 得克萨斯大学体系董事会 Novel htmc promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
CA2752590C (en) * 2009-02-17 2017-08-22 The Trustees Of Columbia University In The City Of New York Identification of extracellular form of pten that can be used to treat tumors
CA3017701C (en) * 2010-02-17 2020-12-15 The Trustees Of Columbia University In The City Of New York Use of pten-long leader sequence for transmembrane delivery of molecules
US9018182B2 (en) * 2010-04-26 2015-04-28 Green Cross Corporation Tumor specific promoter and oncolytic virus vector comprising the same
EP2494978A1 (en) * 2011-03-03 2012-09-05 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses
WO2013169388A1 (en) * 2012-05-08 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy
BR112015022189A2 (en) * 2013-03-13 2017-11-21 Katsura Misako microvesicle, method for its production and use

Also Published As

Publication number Publication date
KR20190035782A (en) 2019-04-03
AU2017301901A1 (en) 2019-02-21
CN110087662A (en) 2019-08-02
WO2018023114A1 (en) 2018-02-01
BR112019001737A2 (en) 2019-05-07
US20230338443A1 (en) 2023-10-26
JP2019523008A (en) 2019-08-22
CA3032412A1 (en) 2018-02-01
EP3490574B1 (en) 2024-05-22
EP3490574A4 (en) 2020-03-04
JP2022163182A (en) 2022-10-25
EP3490574A1 (en) 2019-06-05
US20200085890A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
SG11201900815UA (en) Expression of pten-long with ocolytic viruses
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201809993VA (en) Oncolytic viruses comprising esrage and methods of treating cancer
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201907278VA (en) Anti-tigit antibodies
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201908012SA (en) Cyclic sulfamide compounds and methods of using same
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201908051RA (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201908456VA (en) Linker units and molecular constructs comprising same